NovoCure Limited (NasdaqGS:NVCR) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold NovoCure Limited to reach your target.
Hmm, we can't give any reliable projection for NovoCure Limited's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| NVCR Price (NovoCure Limited stock price per share) |
$10.73 | |
| PE Ratio versus Sector | 0% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 0% lower than other Medical Devices stocks | |
| Free Cash Flow Jitter | 190% |
No open-market insider buys or sells are recorded for the last 12 months.
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 12,913,904 shares shorted. With 97,385,148 shares available for purchase and an average trading volume over the past 10 trading days of 1,722,540, it would take at least 7.5 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
Over the 1 fiscal years from 2013 to 2025 with positive net income, operating cash flow totaled $99.1 million against net income of $19.8 million, or 5.01 times. Net income was negative in 12 of the 13 years, and those years are left out of the ratio.
In 2025, net income was -$136.2 million and operating cash flow was -$49.0 million, so no ratio is shown for that year.
In 2022, capital expenditures were $21.4 million, 69.4% of operating cash flow of $30.8 million, which leaves an estimated $9.4 million after capex. Across the 4 years with reported capex, it averaged 29.7% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2013 | -77.4 | -52.7 | 2.2 | n/a |
| 2014 | -80.7 | -74.2 | 0.8 | n/a |
| 2015 | -111.6 | -99.9 | 4.7 | n/a |
| 2016 | -131.8 | -107.6 | 5.7 | n/a |
| 2017 | -61.7 | -33.1 | 7.4 | n/a |
| 2018 | -63.6 | -1.9 | 6.7 | n/a |
| 2019 | -7.2 | 26.6 | 10.5 | n/a |
| 2020 | 19.8 | 99.1 | 15.0 | 5.01 |
| 2021 | -58.4 | 82.8 | 24.2 | n/a |
| 2022 | -92.5 | 30.8 | 21.4 | n/a |
| 2023 | -207.0 | -73.3 | 27.1 | n/a |
| 2024 | -168.6 | -26.4 | 42.9 | n/a |
| 2025 | -136.2 | -49.0 | 26.6 | n/a |
Revenue was $10.4 million in 2013 and $655.4 million in 2025, a compound annual growth rate of 41.3% over 12 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.
Revenue rose 8.3% from 2024 to 2025.
Our estimated free cash flow was -$77.5 million in 2025, a negative margin of 11.8% of revenue, meaning the estimate was below zero. In 2013 the estimated margin was negative 530.1%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2013 | 10.4 | -54.9 | -530.1% |
| 2014 | 15.5 | -75.8 | -489.1% |
| 2015 | 33.1 | -102.5 | -309.7% |
| 2016 | 82.9 | -110.9 | -133.8% |
| 2017 | 177.0 | -37.3 | -21.1% |
| 2018 | 248.1 | -6.9 | -2.8% |
| 2019 | 351.3 | 19.6 | 5.6% |
| 2020 | 494.4 | 90.1 | 18.2% |
| 2021 | 535.0 | 70.0 | 13.1% |
| 2022 | 537.8 | 15.2 | 2.8% |
| 2023 | 509.3 | -93.0 | -18.2% |
| 2024 | 605.2 | -52.5 | -8.7% |
| 2025 | 655.4 | -77.5 | -11.8% |
In 2025, cash and equivalents were $93.5 million against total liabilities of $463.9 million, or 20.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 57.7% of total assets in 2025, compared with 17.0% in 2014, an increase of 40.7 percentage points.
Stockholders equity was $340.5 million in 2025, compared with $97.9 million in 2014, a rise of 247.9%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -15.9% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2014 | 117.9 | 57.6 | 20.0 | 97.9 |
| 2015 | 307.3 | 119.4 | 56.5 | 250.8 |
| 2016 | 282.1 | 99.8 | 139.7 | 142.3 |
| 2017 | 265.3 | 78.6 | 151.7 | 113.6 |
| 2018 | 339.8 | 140.6 | 227.5 | 112.3 |
| 2019 | 479.4 | 177.3 | 261.7 | 217.8 |
| 2020 | 1052.0 | 234.7 | 575.5 | 476.5 |
| 2021 | 1139.5 | 208.8 | 729.0 | 410.5 |
| 2022 | 1191.6 | 115.3 | 750.5 | 441.2 |
| 2023 | 1146.1 | 240.8 | 783.6 | 362.5 |
| 2024 | 1240.8 | 163.8 | 880.6 | 360.2 |
| 2025 | 804.3 | 93.5 | 463.9 | 340.5 |
Positive free cash flow appears in 4 of the 13 fiscal years we hold for NovoCure Limited from its current SEC filer.
We do not estimate a fair value for NovoCure Limited while its free cash flow growth is not positive, so there is no value comparison here.
Year-to-year variability in free cash flow is volatile, measured at 190%.
Dividends are not in our data for NovoCure Limited.
Before you act on any of this, read what a margin of safety means and check the company's own filings.
Its trailing P/E ratio is in line with the average for stocks in the Healthcare sector.
Its trailing P/E ratio is in line with the average for stocks in the Medical Devices industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
Every fiscal year on this page is reported by one SEC filer, CIK 1645113.
Each figure on this page comes from that filer.
Advertisement supports free stock analysis content.
Does NovoCure Limited have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
We don't yet have enough financial history for NovoCure Limited to produce a full worked example. Check back as more data becomes available, or see the current price and research links below.
Most Popular Articles
What are Broker Fees (and how to pay less)?
What is Liquidity in Stocks and Financial Instruments?